Table 1.

Baseline characteristics

All patients (n = 50)Phase Ib (n = 13)Phase II (n = 37)
VariablesNo.%No.%No.%
Age, years
 Median555358
 Range31–7541–6531–75
Sex
 Male19384311540
 Female31629692260
ECOG PS
 0120013
 14998131003697
Smoking history
 Never30609692157
 Former61218513
 Current14283231130
Pathology
 Adenocarcinoma4896131003595
 Adenosquamous240025
No. of previous chemotherapy regimens
 1–215303231232
 ≥3357010772568
EGFR mutationa
 Exon 19 deletion24488621643
 L858R15302151335
 Complex mutation exon 19240025
 Wild-type714323411
 Unknown240025
Previous EGFR TKIs
 Gefitinib346810772465
 Erlotinib16323231335
Best response to previous EGFR TKI
 Partial response40809693184
 Stable disease816431411
 Progressive disease240025
  • aEGFR mutation status before previous gefitinib or erlotinib therapy.